Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2013

Open Access 01-12-2013 | Research article

Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile

Authors: Diana Carmona-Fernandes, Maria José Santos, Helena Canhão, João Eurico Fonseca

Published in: BMC Medicine | Issue 1/2013

Login to get access

Abstract

Background

This study was devised to assess the performance of anti-ribosomal P (anti-Rib-P) antibodies in the diagnosis of systemic lupus erythematosus (SLE) and the association of these antibodies with the clinical features of SLE.

Methods

We used a fluorescence enzyme immunoassay to determine anti-Rib-P levels in an SLE group, a rheumatic disease control (RDC) group (rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis), and a healthy control (HC) group. We also determined anti-Smith antigen (anti-Sm) and anti-double-stranded DNA (anti-dsDNA) antibody levels. Receiver operating characteristic (ROC) curves were constructed and the best cut-off points for positivity were determined. Using regression analysis, the relationship between clinical variables and autoantibody levels was analyzed.

Results

In total, 127 patients with SLE, 256 controls with other rheumatic diseases, and 100 HCs were studied. Anti-Rib-P autoantibodies were positive in 18 (14.2%) of the patients with SLE (mean concentration of 30.6 ± 46.9 U/ml) and in 2 patients with RA (0.8% of the RDC group). In addition, 12 patients with SLE (9.4%) were positive for anti-Sm (31.1 ± 40.8 U/ml) and 63 (49.6%) were positive for anti-dsDNA autoantibodies (88.4 ± 88.5 U/ml). When we assessed the 18 patients with SLE who had tested positive for anti-Rib-P, we found that 4 of these were positive for anti-Rib-P only, whereas 12 were positive for anti-Rib-P plus anti-dsDNA, and 2 were positive for all three antibodies. There were no samples positive for anti-Rib-P plus anti-Sm. The specificity, sensitivity, positive likelihood ratio, and negative likelihood ratio of anti-Rib-P for SLE diagnosis were 99.4%, 14.2%, 23.7%, and 0.86%, respectively.
Caucasian ethnicity was associated with lower anti-Rib-P antibody levels. No relation was found between anti-Rib-P levels and neuropsychiatric or other clinical features.

Conclusions

Anti-Rib-P autoantibodies have high specificity for SLE, and measurement of these might improve the accuracy of SLE diagnosis. In this study, we found that Caucasian ethnicity was associated with lower anti-Rib-P antibody levels.
Appendix
Available only for authorised users
Literature
1.
Gualtierotti R, Biggioggero M, Penatti AE, Meroni PL: Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev. 2010, 10: 3-7. 10.1016/j.autrev.2010.09.007.CrossRefPubMed
2.
Heinlen LD, Ritterhouse LL, McClain MT, Keith MP, Neas BR, Harley JB, James JA: Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides. J Mol Med. 2010, 88: 719-727. 10.1007/s00109-010-0618-1.CrossRefPubMedPubMedCentral
3.
Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003, 349: 1526-1533. 10.1056/NEJMoa021933.CrossRefPubMed
4.
Doria A, Zen M, Canova M, Bettio S, Bassi N, Nalotto L, Rampudda M, Ghirardello A, Iaccarino L: SLE diagnosis and treatment: when early is early. Autoimmun Rev. 2010, 10: 55-60. 10.1016/j.autrev.2010.08.014.CrossRefPubMed
5.
Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40: 1725.CrossRefPubMed
6.
ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG: Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. 1990, 33: 634-643. 10.1002/art.1780330505.CrossRefPubMed
7.
Gerli R, Caponi L, Tincani A, Scorza R, Sabbadini MG, Danieli MG, De Angelis V, Cesarotti M, Piccirilli M, Quartesan R, Moretti P, Cantoni C, Franceschini F, Cavazzana I, Origgi L, Vanoli M, Bozzolo E, Ferrario L, Padovani A, Gambini O, Vanzulli L, Croce D, Bombardieri S: Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford). 2002, 41: 1357-1366. 10.1093/rheumatology/41.12.1357.CrossRef
8.
Olesinska M, Chwalinska-Sadowska H, Wiesik-Szewczyk E, Mielnik P, Zabek J: Clinical manifestation of systemic lupus erythematosus in patients with antiribosomal P protein antibodies. Pol Arch Med Wewn. 2010, 120: 76-81.PubMed
9.
Agmon-Levin N, Gilburd B, Kivity S, Katz BS, Flitman-Katzevman I, Shoenfeld N, Paran D, Langevitz P, Shoenfeld Y: Anti-ribosomal-P antibodies in lupus patients and healthy controls: evaluation of three ELISA assays. Isr Med Assoc J. 2009, 11: 403-406.PubMed
10.
Mahler M, Ngo JT, Schulte-Pelkum J, Luettich T, Fritzler MJ: Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. Arthritis Res Ther. 2008, 10: R131-10.1186/ar2548.CrossRefPubMedPubMedCentral
11.
Mahler M, Kessenbrock K, Szmyrka M, Takasaki Y, Garcia-De La Torre I, Shoenfeld Y, Hiepe F, Shun-le C, von Muhlen CA, Locht H, Hopfl P, Wiik A, Reeves W, Fritzler MJ: International multicenter evaluation of autoantibodies to ribosomal P proteins. Clin Vaccine Immunol. 2006, 13: 77-83. 10.1128/CVI.13.1.77-83.2006.CrossRefPubMedPubMedCentral
12.
Mahler M, Kessenbrock K, Raats J, Fritzler MJ: Technical and clinical evaluation of anti-ribosomal P protein immunoassays. J Clin Lab Anal. 2004, 18: 215-223. 10.1002/jcla.20026.CrossRefPubMed
13.
Ghirardello A, Doria A, Zampieri S, Gerli R, Rapizzi E, Gambari PF: Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodies. Ann Rheum Dis. 2000, 59: 975-981. 10.1136/ard.59.12.975.CrossRefPubMedPubMedCentral
14.
Haddouk S, Marzouk S, Jallouli M, Fourati H, Frigui M, Hmida YB, Koubaa F, Sellami W, Baklouti S, Hachicha J, Bahloul Z, Masmoudi H: Clinical and diagnostic value of ribosomal P autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford). 2009, 48: 953-957. 10.1093/rheumatology/kep142.CrossRef
15.
Toubi E, Shoenfeld Y: Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev. 2007, 6: 119-125. 10.1016/j.autrev.2006.07.004.CrossRefPubMed
16.
Chandran V, Upadhyaya SK, Haroon N, Aggarwal A, Misra R: Lack of clinical association with antibodies to ribosomal P proteins in Indian patients with systemic lupus erythematosus. J Rheumatol. 2006, 33: 1987-1989.PubMed
17.
Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, Elkon KB: Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med. 1987, 317: 265-271. 10.1056/NEJM198707303170503.CrossRefPubMed
18.
Gladman DD, Ibanez D, Urowitz MB: Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002, 29: 288-291.PubMed
19.
Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A: The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996, 39: 363-369. 10.1002/art.1780390303.CrossRefPubMed
20.
Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsanoja R, Auvinen A: Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum. 2001, 45: 419-423. 10.1002/1529-0131(200110)45:5<419::AID-ART360>3.0.CO;2-X.CrossRefPubMed
21.
Al-Jabri AA, Al-Gahdani AK, Al-Shuaili I: High frequency of Smith autoantibodies in Omani patients with systemic lupus erythematosus. Rheumatol Int. 2009, 30: 51-56. 10.1007/s00296-009-0909-4.CrossRefPubMed
22.
Zandman-Goddard G, Gilburd B, Shovman O, Blank M, Berdichevski S, Langevitz P, Shoenfeld Y: The homogeneous multiplexed system—a new method for autoantibody profile in systemic lupus erythematosus. Clin Dev Immunol. 2005, 12: 107-111. 10.1080/17402520500116723.CrossRefPubMedPubMedCentral
23.
Alba P, Bento L, Cuadrado MJ, Karim Y, Tungekar MF, Abbs I, Khamashta MA, D'Cruz D, Hughes GR: Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis. 2003, 62: 556-560. 10.1136/ard.62.6.556.CrossRefPubMedPubMedCentral
24.
Lin JL, Dubljevic V, Fritzler MJ, Toh BH: Major immunoreactive domains of human ribosomal P proteins lie N-terminal to a homologous C-22 sequence: application to a novel ELISA for systemic lupus erythematosus. Clin Exp Immunol. 2005, 141: 155-164. 10.1111/j.1365-2249.2005.02816.x.CrossRefPubMedPubMedCentral
25.
Metz CE: Basic principles of ROC analysis. Semin Nucl Med. 1978, 8: 283-298. 10.1016/S0001-2998(78)80014-2.CrossRefPubMed
26.
Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993, 39: 561-577.PubMed
27.
Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Clarke A, Bernatsky S, Vasudevan A, Isenberg D, Rahman A, Wallace DJ, Fortin PR, Gladman D, Romero-Dirz J, Sanchez-Guerrero J, Dooley MA, Bruce I, Steinsson K, Khamashta M, Manzi S, Ramsey-Goldman R, Sturfelt G, Nived O, van Vollenhoven R, Ramos-Casals M, Aranow C, Mackay M, Kalunian K, Alarcon GS, Fessler BJ: Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011, 70: 1726-1732. 10.1136/ard.2010.148502.CrossRefPubMedPubMedCentral
28.
Briani C, Lucchetta M, Ghirardello A, Toffanin E, Zampieri S, Ruggero S, Scarlato M, Quattrini A, Bassi N, Ermani M, Battistin L, Doria A: Neurolupus is associated with anti-ribosomal P protein antibodies: an inception cohort study. J Autoimmun. 2009, 32: 79-84. 10.1016/j.jaut.2008.12.002.CrossRefPubMed
29.
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999, 42: 599-608.
30.
Nived O, Sturfelt G, Liang MH, De Pablo P: The ACR nomenclature for CNS lupus revisited. Lupus. 2003, 12: 872-876. 10.1191/0961203303lu495oa.CrossRefPubMed
31.
Roy S, Tan KT: Pyrexia and normal C-reactive protein (CRP) in patients with systemic lupus erythematosus: always consider the possibility of infection in febrile patients with systemic lupus erythematosus regardless of CRP levels. Rheumatology (Oxford). 2001, 40: 349-350. 10.1093/rheumatology/40.3.349.CrossRef
32.
de Carvalho JF, Hanaoka B, Szyper-Kravitz M, Shoenfeld Y: C-reactive protein and its implications in systemic lupus erythematosus. Acta Reumatol Port. 2007, 32: 317-322.PubMed
33.
Wang CL, Ooi L, Wang F: Prevalence and clinical significance of antibodies to ribonucleoproteins in systemic lupus erythematosus in Malaysia. Br J Rheumatol. 1996, 35: 129-132. 10.1093/rheumatology/35.2.129.CrossRefPubMed
34.
Combe B, Rucheton M, Graafland H, Lussiez V, Brunel C, Sany J: Clinical significance of anti-RNP and anti-Sm autoantibodies as determined by immunoblotting and immunoprecipitation in sera from patients with connective tissue diseases. Clin Exp Immunol. 1989, 75: 18-24.PubMedPubMedCentral
35.
Kiss E, Lakos G, Szegedi G, Poor G, Szodoray P: Anti-nuscleosome antibody, a reliable indicator for lupus nephritis. Autoimmunity. 2009, 42: 393-398. 10.1080/08916930903002446.CrossRefPubMed
36.
Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P: Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012, 64: 2677-2686. 10.1002/art.34473.CrossRefPubMedPubMedCentral
Metadata
Title
Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile
Authors
Diana Carmona-Fernandes
Maria José Santos
Helena Canhão
João Eurico Fonseca
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2013
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-11-98

Other articles of this Issue 1/2013

BMC Medicine 1/2013 Go to the issue

Review

A narrative review on the similarities and dissimilarities between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness behavior

Research article

Additional Saturday rehabilitation improves functional independence and quality of life and reduces length of stay: a randomized controlled trial

Debate

When to start antiretroviral therapy: the need for an evidence base during early HIV infection

Review

Peri-operative interventions producing better functional outcomes and enhanced recovery following total hip and knee arthroplasty: an evidence-based review

Review

Novel aspects of Sjögren’s syndrome in 2012

Research article

The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials